Kurzfassung

A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to darcarbazine in the treatment of patients with non-resectable or metastatic stage 3 of stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit